SAN DIEGO, Sept. 26 /PRNewswire-FirstCall/ -- Nanogen, Inc.
(Nasdaq: NGEN), developer of advanced diagnostic products, announced today it
was issued Patent No. 6,942,778, "Microstructure Apparatus and Method for
Separating Differently Charged Molecules Using an Applied Electric Field" by
the U.S. Patent and Trademark Office. The '778 patent relates to a biological
screening device used to monitor the activity of kinase, protease or
phosphatase enzymes on peptide substrates. The device may be used to monitor
a change in net charge of a target molecule as a result of enzyme activity.
The technology described in Nanogen's 132nd patent also allows for simpler,
faster and safer molecular analyses using fluorescent labeling.
Kinase dependant phosphorylation screening is often used in drug discovery
research to determine if lead drug candidates have an effect on the target of
interest. Kinase activity can be monitored through a change in the net charge
of the peptide of interest. This device provides a simple solution to
separate peptides or other differentially charged molecules in a sample for
detection and quantification of a molecule of interest. Using electronic
technology for the separation of kinases and substrates results in fewer false
negatives and false positive results. This device uses fluorometry to detect
kinase activity and eliminates the need for radioactive isotopes. The more
precise quantitative assessment of kinase activity of Nanogen's device
provides a faster means of identifying targets in drug discovery.
About Nanogen, Inc.
Nanogen's advanced diagnostics provide researchers, clinicians and
physicians worldwide with improved methods and tests to predict, diagnose and
ultimately help treat disease. The company's products include real-time PCR
reagents, the NanoChip(R) Molecular Biology Workstation platform for molecular
diagnostic applications and a line of rapid point-of-care diagnostic tests.
Nanogen's ten years of pioneering research involving nanotechnology holds the
promise of miniaturization and continues to be supported for its potential for
diagnostic and biowarfare applications. For additional information please
visit Nanogen's website at www.nanogen.com.
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
patents owned or licensed by Nanogen will be developed into products, whether
the patents owned by Nanogen offer any protection against competitors with
competing technologies, whether products under development can be successfully
developed and commercialized, whether results reported by our customers or
partners can be identically replicated, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. Nanogen disclaims any intent or obligation to update these
SOURCE Nanogen, Inc.